---
title: "Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294366513.md"
description: "Cingulate Inc. published Phase 3 trial results for its ADHD candidate CTx-1301 in the Journal of Child and Adolescent Psychopharmacology. The study demonstrated meaningful symptom improvement versus placebo across tested doses, supporting once-daily use in children and adolescents. With a favorable safety profile, Cingulate plans to advance CTx-1301 toward potential regulatory filing and commercialization."
datetime: "2026-07-30T12:33:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294366513.md)
  - [en](https://longbridge.com/en/news/294366513.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294366513.md)
generator: "portal-rs"
---

# Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology

-   Cingulate disclosed open-access publication of Phase 3 results for ADHD candidate CTx-1301 in the Journal of Child and Adolescent Psychopharmacology. \* Results were already presented in the peer-reviewed paper, not flagged for a future medical meeting. \* Trial showed meaningful symptom improvement versus placebo across tested doses, supporting once-daily use in children and adolescents. \* Safety profile was described as favorable, reinforcing plans to advance CTx-1301 toward potential regulatory filing and commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300830PRIMZONEFULLFEED9800711) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CING.US](https://longbridge.com/en/quote/CING.US.md)
- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [Cingulate price target lowered to $9 from $10 at Roth Capital](https://longbridge.com/en/news/296734582.md)
- [Cingulate publishes peer-reviewed pharmacokinetic study of ADHD candidate CTx-1301 in CNS Drugs](https://longbridge.com/en/news/295537403.md)
- [SciSparc subsidiary NeuroThera Labs enrolls 26 children in SCI-210 autism trial](https://longbridge.com/en/news/297556067.md)
- [CHICAGO WHITE SOX, CIBC AND LOCAL NONPROFITS UNITE FOR CHILDHOOD CANCER AWARENESS DAY ON SEPTEMBER 6 | CM Stock News](https://longbridge.com/en/news/297935859.md)
- [Kry opens child health clinic in Höör, Sweden](https://longbridge.com/en/news/297520716.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**